Literature DB >> 19951993

Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase.

Minghai Shao1, Liyun Cao, Changyu Shen, Minati Satpathy, Bhadrani Chelladurai, Robert M Bigsby, Harikrishna Nakshatri, Daniela Matei.   

Abstract

Tissue transglutaminase (TG2), an enzyme that catalyzes Ca(2+)-dependent aggregation and polymerization of proteins, is overexpressed in ovarian cancer cells and tumors. We previously reported that TG2 facilitates tumor dissemination using an i.p. xenograft model. Here we show that TG2 modulates epithelial-to-mesenchymal transition (EMT), contributing to increased ovarian cancer cell invasiveness and tumor metastasis. By using stable knockdown and overexpression in epithelial ovarian cancer cells, we show that TG2 induces a mesenchymal phenotype, characterized by cadherin switch and invasive behavior in a Matrigel matrix. This is mediated at the transcriptional level by altering the expression levels and function of several transcriptional repressors, including Zeb1. One mechanism through which TG2 induces Zeb1 is by activating the nuclear factor-kappaB complex. The effects of TG2 on ovarian cancer cell phenotype and invasiveness translate into increased tumor formation and metastasis in vivo, as assessed by an orthotopic ovarian xenograft model. Highly expressed in ovarian tumors, TG2 promotes EMT and enhances ovarian tumor metastasis by activating oncogenic signaling.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951993     DOI: 10.1158/0008-5472.CAN-09-1257

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

Review 1.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.

Authors:  Matthew L Fisher; Jeffrey W Keillor; Wen Xu; Richard L Eckert; Candace Kerr
Journal:  Mol Cancer Res       Date:  2015-05-01       Impact factor: 5.852

3.  Tissue Transglutaminase Mediated Tumor-Stroma Interaction Promotes Pancreatic Cancer Progression.

Authors:  Jiyoon Lee; Salvatore Condello; Bakhtiyor Yakubov; Robert Emerson; Andrea Caperell-Grant; Kiyotaka Hitomi; Jingwu Xie; Daniela Matei
Journal:  Clin Cancer Res       Date:  2015-06-03       Impact factor: 12.531

4.  Targeted Quantitative Profiling of GTP-Binding Proteins in Cancer Cells Using Isotope-Coded GTP Probes.

Authors:  Rong Cai; Ming Huang; Yinsheng Wang
Journal:  Anal Chem       Date:  2018-11-28       Impact factor: 6.986

Review 5.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 6.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

7.  Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.

Authors:  Salvatore Condello; Livia Sima; Cristina Ivan; Horacio Cardenas; Gary Schiltz; Rama K Mishra; Daniela Matei
Journal:  Cancer Res       Date:  2018-03-06       Impact factor: 12.701

8.  Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells.

Authors:  Marc A Antonyak; Bo Li; Lindsey K Boroughs; Jared L Johnson; Joseph E Druso; Kirsten L Bryant; David A Holowka; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

Review 9.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

10.  Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.

Authors:  Seon-Hyeong Lee; Nayeon Kim; Se-Jin Kim; Jaewhan Song; Young-Dae Gong; Soo-Youl Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-21       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.